BRIEF-Teva to raise $7 bln equity, plans $22 bln bond to fund Actavis deal
October 29, 2015 at 09:18 AM EDT
* CEO: Impact from generic competition in 40 mg Copaxone estimated at $1.2 billion revenue, $0.65 EPS in 2017
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.